Portfolio
We seek investments in innovative companies that are developing first-in-class products for growth markets. Investments have been made in various therapeutic areas, including oncology, inflammation, cardiovascular, metabolic and CNS.
Fibrex Medical - Austria | |||
| Fund engagement: | 2006 | Activity: | Drug development Reperfusion injury |
| Status: | Exited - Licensing | Contact: | www.fibrexmedical.com |
Elara Phamraceuticals - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development HIF pathway |
| Status: | Pre-clinical development | Contact: | www.elarapharma.com |
Lipid Therapeutics - Germany | |||
| Fund engagement: | 2008 | Activity: | Drug development Colitis ulcerosa |
| Status: | Partnered - Phase IIB | Contact: | www.lipid-therapeutics.com |
Affectis Pharmaceuticals - Germany | |||
| Fund engagement: | 2005 | Activity: | Drug development Depression |
| Status: | Clinical phase IIA | Contact: | www.affectis.com |
Immatics - Germany | |||
| Fund engagement: | 2004 | Activity: | Drug development Cancer vaccines |
| Status: | Clinical phase IIA | Contact: | www.immatics.com |
Endoart - Switzerland | |||
| Fund engagement: | 2006 | Activity: | Medtech Obesity |
| Status: | Exited - Aquisition | Contact: | n.a. |
Vasopharm - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Traumatic brain injury |
| Status: | Clinical phase IIA | Contact: | www.vasopharm.com |
Hybricore - Germany | |||
| Fund engagement: | 2003 | Activity: | Services Antibody production |
| Status: | Exited - Licensing | Contact: | n.a. |
Combinature - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Anti-infectives |
| Status: | Exited - Secondary transaction | Contact: | n.a. |
Jado Technologies - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Allergy |
| Status: | Clinical phase IIA | Contact: | www.jado-tech.com |
Cenix Bioscience - Germany | |||
| Fund engagement: | 2002 | Activity: | Services RNAi based target discovery |
| Status: | Profitable | Contact: | www.cenix-bioscience.com |
ArthroKinetics - Germany | |||
| Fund engagement: | 2003 | Activity: | Medtech Cartilage replacement |
| Status: | Exited - IPO | Contact: | www.arthro-kinetics.com |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
"Stefan Herr was instrumental not only throughout the creation and founding of Cenix, from the very first conceptual discussions to the launch of the new legal corporate entity back in 1999, but importantly also in the conclusion of both of our subsequent VC investment rounds. The path of a first-time Biotech entrepreneur is a very challenging one for anyone to take, but would have been literally impossible for me without Stefan's support, guidance and mentoring as the company's business co-founder. This served me well, as I continue learning every day, now, in the 10th year of Cenix."
Chris Echeverri, Ph.D.; CEO/CSO, lead scientific founder of Cenix BioScience, Dresden